Central African Republic vs Morocco: Antiretroviral therapy coverage for PMTCT
Central African Republic
69.0%
in 2024
Morocco
72.0%
in 2024
Central African Republic rank
52nd
Morocco rank
49th
Antiretroviral therapy coverage for PMTCT over time
- Central African Republic
- Morocco
How they compare
Morocco currently reports 72.0% against 69.0% in Central African Republic, a difference of 3.0%.
The two have swapped places 6 times across 25 shared years of data; in 2000 it was Morocco ahead.
Central African Republic ranks 52nd and Morocco ranks 49th of 84 countries.
Central African Republic has averaged higher in every one of the 3 decades both report.
Head to head by decade
| Decade | Central African Republic | Morocco | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 9.0% | 3.9% | 5.1% | Central African Republic |
| 2010s | 40.7% | 34.4% | 6.3% | Central African Republic |
| 2020s | 59.2% | 55.8% | 3.4% | Central African Republic |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher antiretroviral therapy coverage for pmtct, Central African Republic or Morocco?
- Morocco, at 72.0% against 69.0% in Central African Republic as of 2024.
- What is the difference in antiretroviral therapy coverage for pmtct between Central African Republic and Morocco?
- 3.0%, with Morocco ahead.
- How many years of comparable data are there for Central African Republic and Morocco?
- 25 years are reported by both, from 2000 to 2024.
- How do Central African Republic and Morocco rank globally for antiretroviral therapy coverage for pmtct?
- Central African Republic ranks 52nd and Morocco ranks 49th of 84 countries.
- Where does this data come from?
- UNAIDS estimates, Joint United Nations Programme on HIV/AIDS (UNAIDS), published as Antiretroviral therapy coverage for PMTCT (% of pregnant women living with HIV). Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Percentage of pregnant women with HIV who receive antiretroviral medicine for prevention of mother-to-child transmission (PMTCT).